Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.620
Open
1.560
VWAP
1.57
Vol
510.34K
Mkt Cap
104.09M
Low
1.530
Amount
803.78K
EV/EBITDA(TTM)
--
Total Shares
65.88M
EV
82.68M
EV/OCF(TTM)
--
P/S(TTM)
--
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
--
--
0.000
-100%
--
--
-0.230
-49.45%
--
--
-0.250
-26.51%
Estimates Revision
Stock Price
Go Down
-2.47%
In Past 3 Month
2 Analyst Rating
Wall Street analysts forecast IOBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOBT is 9.00 USD with a low forecast of 4.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.580
Low
4.00
Averages
9.00
High
14.00
Current: 1.580
Low
4.00
Averages
9.00
High
14.00
H.C. Wainwright
Buy
maintain
$12 -> $14
2025-05-14
Reason
H.C. Wainwright
Price Target
$12 -> $14
2025-05-14
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on IO Biotech to $14 from $12 and keeps a Buy rating on the shares following the Q1 report. The firm cites lower than expected operating expenses for the target increase. The analyst says IO's Phase 3 advanced melanoma data is on track for Q3.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$12
2025-04-01
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12
2025-04-01
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$12
2025-03-05
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12
2025-03-05
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$12
2024-11-12
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12
2024-11-12
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$12
2024-11-06
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12
2024-11-06
Reiterates
Strong Buy
Reason
Morgan Stanley
Matthew Harrison
Buy
Maintains
$4 → $6
2024-09-16
Reason
Morgan Stanley
Matthew Harrison
Price Target
$4 → $6
2024-09-16
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for IO Biotech Inc (IOBT.O) is -1.61, compared to its 5-year average forward P/E of -1.39. For a more detailed relative valuation and DCF analysis to assess IO Biotech Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.39
Current PE
-1.61
Overvalued PE
-0.53
Undervalued PE
-2.26
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.20
Current EV/EBITDA
-0.97
Overvalued EV/EBITDA
1.11
Undervalued EV/EBITDA
-1.50
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
+7.60%
-23.17M
Operating Profit
FY2025Q2
YoY :
+26.74%
-26.22M
Net Income after Tax
FY2025Q2
YoY :
+29.03%
-0.40
EPS - Diluted
FY2025Q2
YoY :
+16.79%
-19.85M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
20.9K
USD
Months
6-9
0
0.0
USD
Months
0-12
4
54.9K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
75.0K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
20.9K
USD
Months
6-9
0
0.0
USD
Months
0-12
4
54.9K
USD
Months
IOBT News & Events
Events Timeline
2025-08-11 (ET)
2025-08-11
08:13:37
IO Biotech says statistical significant missed on primary endpoint for Cylembio
2025-05-23 (ET)
2025-05-23
16:08:41
IO Biotech files to sell 5.62M shares of common stock for holders
2025-05-14 (ET)
2025-05-14
08:07:19
IO Biotech reports Q1 EPS (34c) vs (30c) last year
Sign Up For More Events
Sign Up For More Events
News
9.5
08-14NASDAQ.COMIo Biotech Posts Wider Loss in Q2
9.0
08-14NewsfilterBiotech Stocks Rally as Oncology Market Targets $866B by 2034
9.0
08-11BenzingaIO Biotech's Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year
Sign Up For More News
People Also Watch
TOP
TOP Financial Group Ltd
1.160
USD
-1.69%
NTZ
Natuzzi SpA
3.070
USD
+3.65%
MESA
Mesa Air Group Inc
1.240
USD
+1.22%
STI
Solidion Technology Inc
3.250
USD
+4.17%
PDSB
PDS Biotechnology Corp
1.240
USD
0.00%
INLX
Intellinetics Inc
11.137
USD
-0.56%
DERM
Journey Medical Corp
7.210
USD
-0.83%
RPTX
Repare Therapeutics Inc
1.670
USD
+0.60%
PTHL
Pheton Holdings Ltd
0.730
USD
-2.66%
FAQ
What is IO Biotech Inc (IOBT) stock price today?
The current price of IOBT is 1.58 USD — it has increased 0 % in the last trading day.
What is IO Biotech Inc (IOBT)'s business?
What is the price predicton of IOBT Stock?
What is IO Biotech Inc (IOBT)'s revenue for the last quarter?
What is IO Biotech Inc (IOBT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for IO Biotech Inc (IOBT)'s fundamentals?
How many employees does IO Biotech Inc (IOBT). have?